About Novartis
Novartis is a Healthcare company based in West Lafayette (United States) founded in 1996, and was acquired by Novartis in October 2018. Novartis is recognized as an innovative medicines company globally. It operates on a Direct-to-Consumer (D2C) and Managed Services model. Novartis has raised $108 million across 10 funding rounds from investors including SVB, Novartis and Cincinnati Insurance. Novartis offers products and services including Cosentyx and Zolgensma. Its focus areas include Pharmaceuticals and Innovative Medicines. Its legal entity is Novartis AG. Its competitors include TScan Therapeutics, Lyell Immunopharma and GigaGen; 3 of its 3 listed competitors have raised funding.
Company details
Novartis is established as a leader in innovative medicines, focusing on reimagining healthcare to improve and extend lives. The company operates across multiple therapeutic areas including cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. Solutions are developed to address significant disease burdens, reaching 296 million people worldwide. Research and development efforts are centered on breakthrough science, with a strong emphasis on technology platforms and global health challenges. Operations span various regions, ensuring access to treatments through sustainable business models and value-based pricing.
Products & Services of Novartis
Novartis offers a comprehensive portfolio of products and services, including Cosentyx and Zolgensma.
Cosentyx is used for treating autoimmune skin conditions.
Zolgensma is developed for spinal muscular atrophy treatment.
Apps and channels of Novartis
its YouTube channel Novartis has 49.9K subscribers and 30 videos.
Videos from Novartis
The most watched videos on Novartis's YouTube channel, Novartis (49.9K subscribers). Click a video to play it here.
More on Novartis.
Funding Insights of Novartis
Novartis has successfully raised a total of $108M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $95 million completed in March 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $108M
- Total Rounds 10
- Last Round Post-IPO — $95M
- First Round $7.6M
(Jul 2001)
- Investors Count 12
All 10 funding rounds of Novartis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2014 | $95M | Post-IPO | – | – | – |
| Dec 2010 | $8.1M | Series C | – | – | – |
| Aug 2010 | $15M | Debt – Venture | – | – | |
| Oct 2009 | $26.65M | Series C | – | Indiana University Health | |
| Jan 2008 | $15M | Debt – Venture | – | – | |
| Mar 2007 | $15M | Series C | – | – | |
| Dec 2004 | $23M | Series C | – | – | |
| Aug 2003 | $15M | Series C | – | – | |
| May 2003 | $12.65M | Series B | – | – | – |
| Jul 2001 | $7.6M | Series A | – | – |
13 investors in total: 13 institutional.
Investors in Novartis
Novartis has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Novartis and Cincinnati Insurance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
Biomedical investment financing and active management services. | sanderling.com | |||
Late-stage investments in US tech companies are targeted. | bcvc.com | Cincinnati, United States | ||
A venture fund focused on medical sector investments is managed. | tmvp.com | |||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
CID Capital is engaged in lower-middle-market buyout investments. | 1981 | cidcap.com | Carmel, United States | |
Early-stage life science companies are supported through venture capital. | twivp.com | Indianapolis, United States | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
Healthcare services are delivered through hospitals in Indiana. | 1997 | iuhealth.org | Indianapolis, United States |
Investor details for Novartis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Novartis
5 dated milestones of Novartis across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Novartis is founded.
- Funding First funding round of $7.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $95.0M.
- Exit Acquired by Novartis.
Competitors of Novartis
Novartis has 3 listed competitors in our database, 3 of them funded. They include TScan Therapeutics, Lyell Immunopharma and GigaGen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. |
Detailed competitors of Novartis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Novartis
Websites that share an audience with Novartis (endocyte.com).
Websites whose visitors overlap most with Novartis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nektar.com | 100% | 19.6K | #959,308 | View details | |
| progenics.com | 92% | View details | |||
| mediantechnologies.com | 91% | 7.9K | #2,575,747 | View details | |
| exelixis.com | 89% | 39.1K | #1,001,350 | View details | |
| asco.org | 87% | 552.2K | #102,599 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Novartis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Novartis (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novartis
Complete news archive for Novartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novartis
Novartis was founded in 1996 and raised its 1st funding round 5 years after it was founded.
Novartis is headquartered in West Lafayette, United States. It is registered at West Lafayette, Indiana, United States.
Novartis is a funded company, having raised a total of $108M across 10 funding rounds to date. The company's 1st funding round was a Series A of $7.6M, raised on Jul 2001.
Novartis is established as a leader in innovative medicines, focusing on reimagining healthcare to improve and extend lives. The company operates across multiple therapeutic areas including cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. Solutions are developed to address significant disease burdens, reaching 296 million people worldwide. Research and development efforts are centered on breakthrough science, with a strong emphasis on technology platforms and global health challenges. Operations span various regions, ensuring access to treatments through sustainable business models and value-based pricing.
Novartis's top competitors include Lyell Immunopharma, GigaGen and TScan Therapeutics.
Novartis offers Cosentyx and Zolgensma.
Novartis has 13 investors. Key investors include SVB, Novartis, Cincinnati Insurance, MidCap Financial, and Oxford Finance.
Novartis operates through Novartis Ag.
Yes. Novartis was acquired by Novartis in October 2018.